Compare Heron Therapeutics Inc (HRTX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.52 (market cap $299.40M). The key difference: YieldMax Magnificent 7 Fund of Option Income ETFs is far larger — about 4× Heron Therapeutics Inc's market cap, and YieldMax Magnificent 7 Fund of Option Income ETFs is more actively traded (843,109 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| HRTX | YMAG | |
|---|---|---|
Market Cap | $74.04M | $299.40M |
Volume | 3,668,095 | 843,109 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $15.68 |
52-Week Low | $0.27 | $10.76 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
